1,050
Participants
Start Date
November 15, 2022
Primary Completion Date
March 15, 2024
Study Completion Date
March 15, 2024
Estradiol
Vaginal Insert, 4 mcg tablet
Imvexxy
Estradiol 4 mcg Vaginal Insert
Placebo
Vehicle Vaginal Insert
Site 10102, Upper Saint Clair
Site 10134, Philadelphia
Site 10108, Norfolk
Site 10137, New Bern
Site 10145, New Bern
Site 10110, North Charleston
Site 10113, Norcross
Site 10130, Edgewater
Site 10129, Ormond Beach
Site 10138, Maitland
Site 10107, Miami Lakes
Site 10144, Miami Lakes
Site 10101, Miami Springs
Site 10123, Hialeah
Site 10121, Sunrise
Site 10119, West Palm Beach
Site 10139, Lake Worth
Site 10140, Tampa
Site 10117, Sarasota
Site 10106, New Port Richey
Site 10143, Oldsmar
Site 10116, Palm Harbor
Site 10115, Leesburg
Site 10112, Birmingham
Site 10118, Chattanooga
Site 10104, Wichita
Site 10109, Metairie
Site 10128, Marrero
Site 10122, New Orleans
Site 10120, Fort Worth
Site 10141, Houston
Site 10142, Beaumont
Site 10146, Chandler
Site 10147, North Las Vegas
Site 10111, Las Vegas
Site 10135, San Diego
Site 10103, Sacramento
Site 10124, Sacramento
Site 10105, Saginaw
Site 10154, Seattle
Site 10136, Milford
Site 10126, Lawrenceville
Site 10148, Santa Tecla
Site 10149, San Salvador
Site 10151, San Pedro Sula
Site 10153, San Pedro Sula
Site 10150, San Pedro Sula
Site 10152, San Pedro Sula
Teva Pharmaceuticals USA
INDUSTRY